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ABSTRACT 24 
Objective. Weight regain is associated with the promotion of insulin resistance. The 25 
newly discovered myokine irisin, which was proposed to be involved in the management of 26 
insulin sensitivity, could play a role in this process. This study aimed to investigate the 27 
association between irisin and reduced insulin sensitivity induced by weight regain. 28 
Materials/Methods. Insulin sensitivity was evaluated according to the homeostasis 29 
model assessment of insulin resistance (HOMA-IR) in 136 obese patients who followed an 30 
eight-week hypocaloric diet (30% reduced energy expenditure) to lose weight and were re-31 
evaluated four or six months after treatment. Irisin plasma levels, as well as the levels of 32 
leptin, adiponectin, ghrelin and TNF-α, were quantified in a sub-cohort (n=73) from the 33 
initially studied patients at baseline (T0), at the diet endpoint (T1) and after the follow-up 34 
period (T2).  35 
Results.  After a successful dietary intervention to lose weight, 50% of the patients 36 
who regained the lost weight during the follow-up period were categorized as insulin resistant 37 
(HOMA-IR≥2.5) compared with only 25% of patients who maintained the weight loss 38 
(p=0.018). Importantly, in addition to the well-studied hormones leptin and adiponectin, irisin 39 
plasma levels were statistically associated with several risk factors for insulin resistance. 40 
Indeed, the increased risk of insulin resistance during the follow-up period was related to high 41 
irisin levels at baseline (odds ratio=4.2; p=0.039).  42 
Conclusions. Circulating irisin predicts the insulin resistance onset in association with 43 
weight regain. Therefore, irisin could be secreted as an adaptive response to counteract the 44 
deleterious effect of excess adiposity on glucose homeostasis.  45 
Keywords: FNDC5, hypocaloric diet , insulin sensitivity, weight regain 46 
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AHEAD, Action for Health Diabetes 50 
BMI, Body mass index 51 
FNDC5, Fibronectin type III domain-containing 5 52 
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RESMENA-S, MEtabolic Syndrome REduction in Navarra Study 54 
TNF-α, Tumor Necrosis Factor-alpha 55 
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1. Introduction 58 
Nutritional interventions, such as caloric restriction diets, are currently the most suitable 59 
noninvasive therapeutic approach to promote weight loss in the obese patients [1]. Most 60 
therapeutic trials involving dietary treatments report mean weight losses greater than 5% of 61 
body weight [1]. In addition to reducing body weight, dietary treatments are able to counteract 62 
comorbidities of obesity, including insulin resistance. However, long-term data regarding the 63 
effect of dietary interventions on mortality are disappointed, as was recently determined by 64 
the Look AHEAD (Action for Health Diabetes) study [2]. This fact could be because less than 65 
20% of individuals who attempt to lose weight are able to achieve and maintain a 10% 66 
reduction over a year [3]. This adverse dietary outcome has relevant health consequences 67 
because weight regain may contribute to all-cause mortality [4].  68 
Importantly, it was recently proposed that the deleterious metabolic features associated 69 
with excess body weight are largely related to the presence of insulin resistance [5] because it 70 
is associated with obesity and may increase the risk of all-cause, cancer, and cardiovascular 71 
disease mortality [6, 7].Therefore, research examining the detrimental effects of weight regain 72 
on insulin sensitivity to elucidate the potential mechanisms involved in this process is an 73 
important priority to develop more personalized therapeutic approaches to counteract obesity 74 
and its comorbidities.  75 
Insulin resistance is a pathological condition characterized by a decrease in the 76 
efficiency of insulin to regulate blood sugar levels that occurs in response to a complex 77 
interplay of metabolic and inflammatory mediators of energy balance. In addition to well-78 
studied energy metabolism and insulin resistance-related proteins, such as leptin, adiponectin, 79 
ghrelin and tumor necrosis alpha [8], an exercise-induced peptide known as irisin has recently 80 
been identified [9]. Relevantly, irisin was reported to improve obesity states and glucose 81 
homeostasis and to prolong life expectancy [9]. This protein was initially described as a 82 
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cleavage product of the type I membrane protein fibronectin type III domain-containing 5 83 
(FNDC5) [9]; however, recent crystal structure and biochemical characterization studies of 84 
the FNDC5 ectodomain corresponding to the irisin myokine, indicated that irisin consists of 85 
an N-terminal fibronectin III(FNIII)-like domain attached to a flexible C-terminal able to 86 
form dimers independently of glycosylation [10] 87 
Since its discovery, irisin garnered great attention as it was noted that this peptide 88 
could play an important role in animal and human physiology and biology [11]. Nevertheless, 89 
the  beneficial role attributed to irisin in humans is unclear [12], and the effects of exercise 90 
training on FNDC5 gene expression and irisin levels remain unspecified [9, 13-18].  91 
Although irisin was initially described as an exercise-induced hormone secreted by 92 
muscle [9], and it was found related to other myokines [19], it was also described to behave as 93 
an adipokine expressed and secreted by white adipose tissue (WAT). In particular it was 94 
reported the secretion of irisin mainly by subcutaneous adipocytes in rats and humans 95 
depending on exercise and nutritional status [20]. In addition, it was found that irisin is 96 
expressed in glutamate decarboxylase-positive Purkinje cells of the cerebellum in the brain 97 
[21], and an important role in the neurogenic regulation was suggested [22, 23]. Interestingly, 98 
it appears to have no in vitro effect on cell proliferation and malignant potential of obesity-99 
related cancer cell lines in physiological and higher physiological/pharmacological 100 
concentrations [24]. Moreover, this peptide could influence the regulation of metabolic 101 
pathways, and the postnatal growth and development of different organs in the newborn 102 
because it is present in human breast milk [25].  103 
Lower circulating irisin was associated with the onset of type 2 diabetes [26-28] with 104 
the risk of non-alcoholic fatty liver disease [29], chronic kidney disease [30] and heart failure 105 
[31]. Additionally, oxidative stress and inflammation, which are two mechanisms involved in 106 
the onset of insulin resistance [32], were associated with an increase in irisin levels, as was 107 
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reflected in human muscle [33] and liver [34]. However, the irisin effect appears to be exerted 108 
in a nutrition-independent fashion because its circulating levels were not associated with 109 
dietary indices [35].   110 
The goals of this study were to evaluate the impact of weight regain after a successful 111 
hypocaloric diet-induced weight loss on the prevalence of insulin resistance classified 112 
according to the homeostasis assessment model of insulin resistance (HOMA-IR) and to 113 
explore the association among circulating levels of irisin and the detrimental effect of weight 114 
regain on insulin sensitivity, as well as changes in hormones that can affect insulin resistance 115 
such as leptin, adiponectin, ghrelin and tumor necrosis factor-alpha (TNFα).  116 
 117 
2. Patients and Methods 118 
2.1.Study patients and design 119 
The study protocol included a group of obese patients (n=136; body mass index 33.3±4.4 120 
kg/m
2
; 74 men/62 women; 43.0±11.2 years) who followed an eight-week hypocaloric diet (-121 
30% energy expenditure) to lose weight and were re-evaluated four or six months after 122 
treatment (Fig. 1). The therapy program was based on a nutritional intervention controlled by 123 
trained dieticians from the Department of Nutrition, Food Sciences and Physiology of the 124 
University of Navarra.  125 
Among the total participants, 63 patients (cohort 1; 32 men/31 women) were enrolled in 126 
a nutritional weight loss program that consisted of an eight-week balanced hypocaloric diet 127 
containing 55% of the energy supply as carbohydrates, 15% as proteins, and 30% as fat. Upon 128 
completion of the dietary intervention (week 8; T1), volunteers were given general dietary 129 
guidelines to maintain the weight loss but without calorie restrictions or specific follow-up 130 
instructions. Six months after dieting ended (week 32; T2), the patients returned to the clinical 131 
research unit for further assessment.  132 
7 
 
The additional 73 participants (cohort 2; 42 men/31 women) followed a therapy 133 
program based on the RESMENA-S (MEtabolic Syndrome REduction in Navarra) study, 134 
which was a randomized controlled intervention trial aiming to improve clinical criteria and 135 
biomarkers associated with metabolic syndrome (Met Synd) through a dietary strategy for 136 
weight loss during six months [36, 37]. Briefly, the study lasted six months in two sequential 137 
periods: one intervention period of two months (-30% energy restriction, 40-55%E 138 
carbohydrate/30%E lipids/15-30%E protein) in which subjects were randomly assigned to two 139 
energy-restricted diets (control diet and RESMENA diet) followed by a self-control period of 140 
four months in which subjects were advised to follow the learned-habits in the first period, 141 
which is further described elsewhere [36, 37]. Four months (week 24; T2) upon completion of 142 
the dietary intervention (week 8; T1), subjects returned to the clinical research unit for further 143 
assessment. 144 
In both cohorts, participants were asked to maintain their normal physical activity 145 
during the study and received nutritional assessment every 15 days during the energy restriction 146 
period. Both protocols were approved by the Ethics Committee of the University of Navarra in 147 
accordance with the Declaration of Helsinki (ref 54/2006 and ref 065/2009), and all participants 148 
provided written informed consent.  149 
Before and after the nutritional treatment, selected anthropometric measurements were 150 
taken. Dietary compliance was assessed through 3-days weighed food records [38]. 151 
Calculations of the energy and nutrient intake were performed using appropriate software 152 
(DIAL software; Alce Ingenieria, Madrid, Spain) based on the recognized Spanish food 153 
composition tables. Food questionnaires were completed during the week before the beginning 154 
of the intervention and 1 week before the completion of the hypocaloric diet. These reports 155 
provided information regarding the baseline intake and the adherence to the prescribed diets. 156 
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Anthropometric measurements and venous blood samples were collected after a 12-hour 157 
overnight fast performed according to standardized procedures at baseline (T0), the endpoint 158 
(T1) and the follow-up period (T2). The patient’s EDTA-plasma and serum was separated from 159 
whole blood and immediately frozen at -80ºC until assayed. 160 
 161 
2.2.Anthropometric and body composition measurements 162 
Body weight measurements were performed using a digital balance accurate to 0.1 kg (Tanita 163 
bioelectrical impedance; SC-330, Tanita, Tokyo, Japan), and height was measured using a 164 
wall-mounted stadiometer (Seca 220; Vogel & Halke). The waist circumference was 165 
measured at the site of the smallest circumference between the rib cage and the iliac crest. 166 
Body composition was measured by bioelectrical impedance (SC-330, Tanita, Tokyo, Japan). 167 
All measurements were taken with the subjects in underwear and after an overnight fast. 168 
 169 
2.3.Biochemical and hormonal analysis 170 
Glucose and triacylglyceride serum concentrations were measured in an autoanalyzer Pentra C-171 
200 (HORIBA ABX, Madrid, Spain) with specific kits. Insulin concentrations were assessed 172 
using an enzyme-linked immunosorbent assay (ELISA) kit available from Mercodia, AB 173 
(Uppsala, Sweden) in a Triturus autoanalyzer (Grifols SA, Barcelona, Spain). Insulin resistance 174 
was indirectly determined by the homeostatic model assessment index (HOMA-IR), which was 175 
calculated following the formula [fasting plasma glucose (mg/mL) x fasting plasma insulin 176 
(μU/mL)/405], as described elsewhere [39]. Furthermore, patients were divided into two 177 
categories according to estimated insulin resistance (insulin sensitive: HOMA-IR<2.5; insulin 178 
resistant HOMA-IR≥2.5) following previously reported data [5, 40]. 179 
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The quantitative measurement of irisin in human plasma samples was performed using a 180 
commercial ELISA kit directed against amino acids 31-143, which include the extracellular 181 
part of the protein of the FNDC5 protein (Irisin ELISA Kit EK-067-52; Phoenix 182 
Pharmaceuticals, INC., CA) according to the manufacturer’s instructions. Absorbance from 183 
each sample was measured in duplicate using a spectrophotometric microplate reader at 184 
wavelength of 450 nm (Versamax Microplate Reader; Associates of Cape Cod Incorporated, 185 
East Falmouth, MA).  186 
Overnight fasting plasma levels of leptin, adiponectin and ghrelin were measured by 187 
ELISA using a commercially available kit (Millipore, MA, USA). Fasting serum levels of 188 
TNFα were determined by the Quantikine High-Sensitivity Human TNFα Enzymatic 189 
Immunoassay (R&D Systems, Minneapolis, MN) in a Triturus autoanalyzer (Grifols SA).  190 
 191 
2.4.Statistical analysis 192 
The sample size of these interventional trials was estimated after accounting for the weight loss 193 
after treatment (main variable) and was calculated for an α=0.05 and a power of 80% according 194 
to the equation reported by Mera et al. [41]. Thus, to detect differences, the sample size was 195 
established at a minimum of 66 obese patients who finished the nutritional intervention. The 196 
data from the obese patients were analyzed by the protocol and merged, as they followed a 197 
hypocaloric diet with the same energy restriction, and no differences were observed in the main 198 
variable analyzed (weight loss).  199 
Diet-induced changes in body weight and hormone values were calculated (as 200 
percentages) as the difference between the endpoint (T1) and baseline (T0) measurements and 201 
related to the baseline (T0). Weight regain (percent) was calculated as the difference between 202 
the follow-up period (T2) and endpoint (T1) with respect to the endpoint values (T1). 203 
Successful weight-loss maintenance was assessed using the criterion of less than 10% weight 204 
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regain according to previously published reports [42]. The patients were subsequently sorted in 205 
two groups: those who regained ≥10% of the weight loss (“regainers”) and those who 206 
maintained the weight loss (“non-regainers”). The values of anthropometric and biochemical 207 
parameters at T0, T1 and T2 were compared between the two groups.  208 
Previously, the normal distribution of variables was explored using the Kolmogorov-209 
Smirnov and the Shapiro Wilk tests. An ANCOVA was used to study differences between 210 
groups adjusted for gender and cohort as applicable. Moreover, a repeated-measures ANCOVA 211 
was used to study the effects of the time of the nutritional therapy program and groupings on 212 
body weight and biochemical parameters in the obese patients adjusted for gender and cohort. 213 
The Chi-square (χ2) test was used to compare the prevalence of insulin resistance between 214 
regainers and non-regainers. The potential associations between anthropometric and 215 
biochemical parameters were evaluated using the Spearman coefficient test. To analyze the 216 
effect of high or low hormone levels on insulin sensitivity, the median (above and below the 217 
50
th
 percentile) cutoff values in the irisin, leptin, adiponectin, ghrelin and TNFα were 218 
considered in the analyzed population, as previously applied [42] and based on a validated 219 
method to assign the studied population into two groups of disease risk [43]. In addition, a 220 
logistic regression analysis was applied to assess the potential predictive factors of insulin 221 
resistance risk during the weight maintenance period (T2). Insulin resistant categories at T2 222 
were used as the dependent variable, and median cut-off values of hormone levels at baseline 223 
(T0) or at follow-up (T2) were used as independent variables.  The logistic regression models 224 
were adjusted for gender, age, body weight at follow-up (T2), insulin sensitivity state 225 
(according to the HOMA-IR≥2.5 cut-off criteria) at baseline (T0) and change (%) in fat mass.  226 
Statistical analysis was performed using SPSS version 15.0 software (SPSS Inc., 227 
Chicago, IL) for Windows XP (Microsoft, Redmond, WA). P≤0.05 was considered to be 228 
statistically significant.  229 
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3. Results 230 
As designed, the hypocaloric diet induced a statistically significant weight loss (-6.31±0.195%; 231 
p<0.001, adjusted for gender and cohort) and a reduction in body mass index (BMI), waist 232 
circumference and body fat mass in the patients as a group (data not shown). After the follow-233 
up period (T2), as a group, patients continued to decrease their body weight compared with the 234 
endpoint (T1) of the energy restriction treatment (89.0±1.0 kg vs. 87.2±1.1 kg; p<0.001, 235 
adjusted for gender and cohort). However, when the participants in the current study were 236 
categorized according to the 10% of weight regain classification criterion, 75 subjects 237 
maintained the weight loss (non-regainers), and 61 subjects regained (regainers) at least 10% of 238 
the weight loss at T2. The analysis of the clinical characteristics of the patients revealed no 239 
significant differences in age, body weight, body fat mass or waist circumference between 240 
regainers and non-regainers at baseline (Table 1). Nevertheless, an expected, statistically 241 
significant (p<0.05), higher body weight was observed in regainers compared with non-242 
regainers, along with a higher BMI, waist circumference and fat mass at T2 (Fig. 2). No 243 
differences were observed in fat free mass between both groups (58.79±1.24 kg non-regainers 244 
vs. 60.85±1.23 kg regainers; p=0.252, adjusted for gender and cohort). These anthropometric 245 
differences between both groups were concomitant with statistically significant (p<0.05) 246 
elevated levels of glucose and insulin, as well as HOMA-IR, in regainers compared with non-247 
regainers (Fig. 2).  248 
As expected, the percentage change in HOMA-IR from T0 to T2 was statistically 249 
correlated with the percentage of weight regain (r=0.41; p<0.001), suggesting that unsuccessful 250 
weight maintenance is associated with a reduced insulin sensitivity. To investigate the 251 
association between insulin sensitivity and weight regain further, patients were first classified 252 
according to the changes in HOMA-IR from T0 to T2 into three groups; “improving group” 253 
(∆HOMA-IR <-0.01), “worsening group” (∆HOMA-IR>0.01) and “non-change group” (-254 
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0.009>∆HOMA-IR<0.009). Under these conditions, approximately 32% (n=43/136) of the 255 
subjects exhibited reduced insulin sensitivity from T0 to T2 as demonstrated by an HOMA-IR 256 
increase greater than 0.01 units (Fig. 3A). This reduced insulin sensitivity was observed in 257 
34.4% (n=21/61) of regainers and in 29.3% (22/75) of non-regainers.   258 
Importantly, when patients were categorized as insulin resistant or insulin sensitive 259 
according to the HOMA-IR≥2.5 cut-off criteria [5, 40], 18.0% of regainers exhibited worsened 260 
insulin sensitivity from a state of insulin sensitivity at T0 to insulin resistance at T2, and only 261 
16.4% of regainers improved their insulin sensitivity during the therapy program (Fig. 3B). In 262 
contrast, among the non-regainers, only 9.3% of insulin sensitive patients at T0 were classified 263 
as insulin resistant at T2, whereas 30.7% of non-regainers improved their insulin sensitivity at 264 
T2 from their insulin resistance condition at T0 (p=0.018, compared with regainers; Fig. 3B).   265 
Taking into account that insulin sensitivity is influenced by several energy metabolism-266 
related proteins and that the newly discovered myokine irisin is proposed to be involved in the 267 
management of insulin sensitivity [9], the circulating levels of irisin as well as the levels of 268 
leptin, adiponectin, ghrelin and TNFα were evaluated as potential factors associated to the 269 
decrease in insulin sensitivity. Due to insufficient blood sample for this aim in overall patients 270 
included in this study this objective was performed specifically in the cohort 2 (n=73; Fig. 1). 271 
Interestingly, although there was no statistical correlation with glucose levels, irisin 272 
plasma levels at T0 and at T2 were statistically associated with the circulating levels of insulin 273 
and with the HOMA-IR,  as well as with the circulating triacylglycerides (Table 2). Indeed, at 274 
baseline (T0), circulating insulin was identified an independent factor affecting the irisin 275 
plasma levels, after adjusting for gender and BMI, (β=6.21; 95%CI: 0.06-12.35; p=0.048).  276 
In addition, circulating levels of leptin, adiponectin, ghrelin and TNFα at T0 and T2 277 
were also statistically correlated with several risk factors of insulin resistance, such as waist 278 
circumference and glucose, insulin, triacylglycerides and HOMA-IR levels (Table 2). Thus, the 279 
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studied insulin resistance risk factors were directly associated with the circulating levels of 280 
irisin, leptin and TNFα and were inversely correlated with adiponectin. An inverse association 281 
was also observed between ghrelin levels and waist circumference (Table 2). The cross 282 
correlation of the hormones showed that irisin levels at T0 were inversely associated with 283 
ghrelin at T0 and TNFα at T2 (Table 2).  No association was detected between irisin and leptin 284 
or adiponectin.   285 
To further investigate the influence of irisin levels on the impairment of insulin 286 
sensitivity, the patients were categorized into two groups according to the median baseline (T0) 287 
irisin plasma levels. Patients exhibiting irisin plasma levels above the median showed 288 
statistically higher HOMA-IR in the weight maintenance period (p=0.012) than those with 289 
irisin levels below the median after adjusting for age and gender (Fig. 4). In addition, the 290 
effects of adiponectin, leptin, ghrelin and TNFα were explored in the same manner, observing 291 
that baseline circulating leptin levels above the median were accompanied by increased follow-292 
up HOMA-IR (p=0.005), and no differences in HOMA-IR were observed according to the 293 
baseline adiponectin, ghrelin and TNFα levels (Fig. 4). These results were also observed when 294 
patients were divided according to the median irisin, adiponectin, leptin, ghrelin and TNFα 295 
levels at follow-up (T2), with significant differences detected specifically according to irisin 296 
and leptin levels (Fig. 4).  297 
Reinforcing these findings, a logistic regression analysis (Table 3) revealed that high 298 
irisin levels at baseline (odds ratio=4.2; p=0.039) and a trend at follow-up (odds ratio=3.6; 299 
p=0.088), as well as high follow-up leptin levels (odds ratio=10.8; p=0.008), predicted an 300 
increased risk of insulin resistance during the follow up period (T2) independently of gender, 301 
age, body weight at T2, and insulin sensitivity state at T0 (Table 3). These statistically 302 
significant associations remained after adjusting for the change in fat mass from the end of the 303 
dietary treatment to follow-up (Table 3).  304 
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When patients were categorized according to their success in weight maintenance, no 305 
statistically significant differences (p>0.05) were observed at baseline (T0) between regainers 306 
and non-regainers. At follow up (T2), regainers, who were more often associated with 307 
decreased insulin sensitivity, exhibited statistically higher irisin and leptin levels than did non-308 
regainers (Table 4). Although adiponectin did not predict insulin sensitivity with statistical 309 
significance in the patients as a group, statistically significant lower adiponectin levels were 310 
observed in regainers compared with non-regainers at follow–up, whereas no differences were 311 
observed in ghrelin and TNFα between the two groups.  312 
 313 
4. Discussion 314 
The current findings indicate that a high proportion of patients who follow a dietary 315 
intervention to lose weight are prone to decreased insulin sensitivity over the period of free-316 
living despite successful weight loss and an improvement in insulin sensitivity induced by the 317 
dietary weight-lowering program. This decreased insulin sensitivity was especially relevant in 318 
those patients who regained their lost weight, which reinforces the main concern of identifying 319 
robust biological markers able to detect patients who are more likely to regain diet-induced 320 
weight loss early [42, 44] and to guide appropriate therapy and thereby improve clinical 321 
outcomes. Among the potential factors associated with this insulin resistance progress, irisin 322 
appears to play a role in addition to leptin and adiponectin, both of which are proteins with a 323 
highly demonstrated insulin resistance relationship. Therefore, irisin could play a role in 324 
promoting insulin resistance or be an adaptive response to counteract the glucose homeostasis 325 
disturbance in obesity.  326 
The application of a balanced hypocaloric diet for weight loss in the current work 327 
improved glucose, insulin and HOMA-IR levels. This insulin sensitivity improvement during 328 
an energy restriction phase was previously associated with a lower subsequent weight regain 329 
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[45].  However, when the subjects included in this study were categorized into two groups 330 
according to their success in body weight maintenance, those subjects who regained at least 331 
10% of the lost weight experienced an increase in their glucose, insulin and HOMA-IR levels, 332 
whereas the subjects who maintained or continued to decrease their body weight exhibited 333 
decreasing values of the glucose regulatory parameters evaluated, which is in agreement with 334 
previous findings [4]. This deleterious effect observed during a free-living phase of a 335 
nutritional intervention to lose weight appears to be prevented when patients followed 336 
behavioral strategies for maintaining weight loss and they were in continuous supervision [46], 337 
instead of a free-living phase after dieting.  338 
Insulin sensitivity is modulated by several adipose-derived hormones, such as 339 
adiponectin and leptin. Adiponectin is considered an insulin sensitizer, has antidiabetic 340 
properties and decreased adiponectin levels are associated with obesity and insulin resistance 341 
[47]. Leptin collaborates with insulin to regulate glucose and lipid metabolism, in addition to 342 
regulating food intake and metabolic rate via the central nervous system [48]. However, 343 
increased leptin concentration is associated with obesity and insulin-resistant states, suggesting 344 
that obese individuals display leptin resistance [49].  345 
Recently, a muscle-secreted peptide named irisin was identified and proposed to play an 346 
important role in improving obesity and glucose homeostasis [9, 50]. Like leptin, irisin has 347 
attracted considerable attention because it has been proposed to have therapeutic potential for 348 
obesity and diabetes and to improve life expectancy. However, in a manner similar to leptin, 349 
irisin circulating concentrations [51-53] as well as its expression in muscle and adipose tissue 350 
[20, 54] is increased in obesity, which suggests potential irisin resistance [55] as occur with 351 
leptin.  352 
Given this prior knowledge, the present study explored the association between the 353 
insulin sensitivity in a weight regain condition with irisin plasma levels and other hormones 354 
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related to body weight homeostasis. The findings identified irisin and leptin as relevant factors 355 
that may contribute to the onset of insulin resistance. The risk of insulin resistance at follow-up 356 
was higher in those patients with high levels of irisin and leptin. Although adiponectin has been 357 
demonstrated to have an insulin-sensitizing activity [47], no association was observed between 358 
the insulin resistance during the weight maintenance period and adiponectin levels. In fact, only 359 
high irisin plasma levels at baseline were able to predict the classification of patients as insulin 360 
resistant during the weight maintenance period, independent of gender, body weight at follow-361 
up and insulin sensitivity state at baseline and even when the change in fat mass from the end 362 
of the dietary treatment to follow-up was included as a confounder factor.  363 
Interestingly, when the patients were categorized according to their successes in weight 364 
maintenance at follow-up, the decreased insulin sensitivity that was observed more frequently 365 
in the regainer group, was accompanied by a greater increase in irisin and leptin levels as well 366 
as smaller increases in adiponectin than did non-regainers during the follow-up period. 367 
Therefore, in addition to the expected contribution of leptin and adiponectin changes, the 368 
insulin resistance observed in regainers occurred concomitantly with increased levels of irisin 369 
during the free-living follow-up period.  370 
The current results are in agreement with recent reports in which a positive association 371 
was observed between circulating irisin levels or FNDC5 expression in human myotubes and 372 
fasting insulin concentrations and HOMA-IR [18, 56]. Additionally, during the peer-review 373 
process of the current work, an independent study reported a significant positive correlation 374 
between baseline circulating irisin levels and insulin resistance as assessed by HOMA-IR [57].  375 
In contrast, three previous reports [26-28] observed a decreased level of circulating 376 
irisin in patients with type 2 diabetes compared with normal glucose tolerance subjects. 377 
However, the subjects included in these studies exhibited a low degree of obesity, whereas in 378 
the current work, the mean of body mass index was 33.5 kg/m
2
. In fact, circulating irisin 379 
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correlated positively with most known markers of insulin resistance in non-diabetic individuals 380 
[27]. All together the current and previous results support the hypothesis that increased 381 
circulating irisin is an adaptive response to compensate for the decreasing insulin sensitivity 382 
and disturbances in metabolism associated with obesity [51, 58]. Though irisin is also secreted 383 
by adipose tissue [20], the reduced irisin levels displayed in type 2 diabetes [26-28] may be due 384 
to the decrease of body fat stores in uncontrolled insulin-deficient diabetes as occur with leptin 385 
[59]. On the other hand, it could be speculated that in obesity a long-term increase in irisin 386 
becomes a pathological condition that promotes insulin insensitivity. The potential resistance to 387 
irisin displayed in obesity could promote insulin secretion resulting in hyperinsulinemia and 388 
leading to insulin resistance. However, these hypotheses remain to be demonstrated and it 389 
cannot be elucidated by the current work.  390 
The strength of this study is its longitudinal design, which allows the evaluation of the 391 
time-course of changes of insulin resistance risk factors in parallel with irisin circulating levels 392 
and other insulin sensitivity-related hormones, as well as differences between regainers and 393 
non-regainers of body weight. In fact, this study provides, for the first time, evidence revealing 394 
that insulin resistance associated with weight regain during the free-living period after a diet-395 
induced weight loss can be predicted by the newly discovered myokine irisin. 396 
Possible limitations of the current study warrant consideration before interpretation of 397 
the findings. First, the sample size of this study limited the inclusion of potentially relevant co-398 
variables such as physical activity, smoking status, or dietary variables that could help to build 399 
a best prediction model of the insulin resistance risk during the free-living period after dieting. 400 
However, the statistical significance found when using small populations usually indicates that 401 
there is a real difference between the experimental groups. In fact, although the sample size of 402 
this trial was not estimated based on the irisin levels because it was a secondary outcome in 403 
response to the potential role of irisin as a therapeutic target of metabolic disorders in the last 404 
18 
 
months, this study had over 93% power to detect the differences in irisin circulating levels 405 
between regainers and non-regainers. Secondly, because this report describes an observational 406 
association study, this work can only propose hypotheses and mechanisms potentially 407 
underlying the association between insulin resistance and irisin, adiponectin and leptin, rather 408 
than demonstrating causality. On the other hand, there has been controversy regarding the 409 
stability and range of the commercially available irisin ELISA kits, as this field needs a 410 
validated antibody that can quantify levels of FNDC5/irisin protein in plasma [60]. In the 411 
current work, the ELISA kit employed was directed against amino acids 32 to 143 which 412 
include the extracellular part of the protein according to manufacturer information (Phoenix 413 
pharmaceuticals); this kit was the same one employed in previous studies in humans [51, 52, 414 
57]. In addition, all of the samples in this study were analyzed using the same kit lot number to 415 
avoid bias. Therefore, the current results of the irisin plasma levels are robust and comparable 416 
with previous findings in humans. 417 
In summary, the current findings adds consistent information concerning the  418 
association between circulating irisin levels and the prevalence of insulin resistance in weight 419 
regain patients after a dietary weight-lowering program in obese humans. These observations 420 
are of foremost relevance, as they demonstrate that energy restriction treatment could be 421 
harmful for an important number of obese treated patients, promoting insulin resistance in a 422 
short time, which, consequently, could lead to type 2 diabetes mellitus onset in the future. More 423 
novelty, the translational potential of the current findings is that evaluating the circulating irisin 424 
values at baseline could predict future disturbance in glucose homeostasis during the free-living 425 
time after a dietary treatment. Further mechanistic studies are needed to elucidate whether irisin 426 
is a promoter of insulin resistance or whether irisin levels represent an adaptive response 427 
induced by insulin signaling to counteract the glucose homeostasis disturbance induced in 428 
obesity. 429 
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FIGURE LEGENDS 619 
Fig. 1. Schematic overview of the study protocol. CHO, carbohydrates; prot., proteins; 620 
lip., lipids; RESMENA, MEtabolic Syndrome REduction in NAvarra; TNFα, tumor necrosis 621 
factor-alpha.  622 
Fig.  2. Body mass index (BMI), waist circumference, percent fat mass, plasma 623 
glucose, insulin levels and Homeostatic model assessment index-insulin resistance (HOMA-624 
IR) during the nutritional treatment (T0-T1) and after the 4-6 months follow-up period (T2) as 625 
a function of the success in weight maintenance (non-regainers, n=75 and regainers, n=61). 626 
The data are presented as the mean (SE). ‡, statistically significant differences (p<0.001) from 627 
T0 to T1 as evaluated by means of a repeated-measures ANCOVA adjusted for gender and 628 
cohort. §, statistically significant (p<0.05) changes over the duration of the nutritional 629 
program (from T0 to T1 and T2). †, statistical significance for the interaction between time x 630 
regaining group (non-regainers, regainers) as evaluated by means of a repeated-measures 631 
ANCOVA adjusted for gender and cohort. Statically significant differences between regainers 632 
and non-regainers were evaluated by ANCOVA adjusted for gender and cohort and are 633 
indicated as *p<0.05.  634 
Fig. 3. (A) Distribution of the patients (n=136) classified according to the changes in 635 
HOMA-IR from baseline (T0) to follow-up (T2) in three groups: improving group (∆HOMA-636 
IR <-0.01), worsening group (∆HOMA-IR>0.01) and non-change group (-∆HOMA-637 
IR±0.009). (B) Prevalence of insulin resistance according to the HOMA-IR ≥2.5 classification 638 
criterion at T2 compared with that at T0 among regainers (n=61) and non-regainers (n=75) of 639 
at least 10% of lost weight. Statistical significance was evaluated by the χ2 test. 640 
Fig. 4. Differences in HOMA-IR values at follow-up (T2) of cohort 2 patients (n=73) 641 
categorized according to the median of the irisin, adiponectin, leptin, ghrelin and tumor 642 
necrosis factor-alpha (TNFα) levels at baseline (T0) and at follow-up (T2). Data are presented 643 
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as the mean (SE). Statistically significant differences between both groups were evaluated by 644 
ANCOVA adjusted for gender and diet (control and RESMENA) are indicated as *p<0.05. 645 
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